Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Stellar Announces $3.6 Million Private Placement

Abstract:
Stellar Biotechnologies, Inc. (the "Company" or "Stellar", TSX.V: KLH) announces a non-brokered private placement financing consisting of up to 6,000,000 units (the "Units") at a purchase price of $0.60 per Unit to raise gross proceeds of up to $3,600,000 (the "Private Placement").

Stellar Announces $3.6 Million Private Placement

Port Hueneme, CA | Posted on October 26th, 2010

Each Unit will consist of one common share in the capital of the Company and one transferable share purchase warrant. Each warrant will entitle the holder to purchase one additional common share in the capital of the Company for a period of two years from the date of issuance, at a purchase price of $0.90 per share during the first year and $1.15 per share during the second year.

The Company may pay a finder's fee in accordance with the policies of the Exchange and subject to the approval of the TSX Venture Exchange.

The securities issued will be subject to a hold period of four months and one day.
Proceeds of the Private Placement will be used for corporate purposes, including the completion of the development and regulatory process for IMG KLH and the Stellar KLH/IMG-based primary immune diagnostic product as envisioned in the Company's Filing Statement dated December 22, 2009, as well as the commercial launch of the new, KLH-based product line. Given current plans, Stellar expects this funding to fulfill the Company's capital needs into 2012.

The Company was approached by a very limited group of substantial, long-term investors to complete this financing. In Management's opinion this represents the best financing opportunity available to the Company and will allow it to advance the business toward the achievement of all its current goals, including those discussed in the Filing Statement.

The Private Placement will be subject to approval by the TSX Venture Exchange.

Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.

####

About Stellar Biotechnologies
Stellar’s product, KLH, is a potent immuno-stimulatory protein with an exceptional record of safety and non-toxicity in humans that is being used in medicines known as conjugate therapeutic vaccines and in other biomedical products. Already a world leader in the production of KLH, Stellar plans to further monetize its KLH production platform and maximize the commercial impact of its intellectual property portfolio through the physical sourcing, purification and supply of medical-grade KLH. KLH is exclusively sourced from the blood of the rare keyhole limpet and Stellar has technology for the maintenance of that animal, as well as a non-lethal extraction method of the critical molecule and refinement process for KLH that it currently sells into growing academic, research, pharmaceutical markets.

For more information, please click here

Contacts:
Darrell Brookstein, Executive VP, Business Development & Finance

Copyright © Stellar Biotechnologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Compact, Low Cost, Accurate: Mini Positioning Stages, by PI June 30th, 2015

NEI Announces the Issuance of Multiple Patents on Self-Healing & Superhydrophobic Coatings June 30th, 2015

Philips Introduces Quantum Dot TV with Color IQ™ Technology from QD Vision: Manufacturer is first to offer quantum dot displays for both TVs and monitors June 30th, 2015

Oxford Instruments’ TritonXL Cryofree dilution refrigerator selected for the Oxford NQIT Quantum Technology Hub project June 30th, 2015

Investments/IPO's/Splits

Nanometrics to Participate in 7th Annual CEO Investor Summit 2015: Investor Event Held Concurrently With SEMICON West in San Francisco June 25th, 2015

Harris & Harris Group Portfolio Company D-Wave Systems Announces 1,000 Qubit Processor and is Discussed in the Economist June 23rd, 2015

Nanowire LED Innovator Aledia Completes $31 Million Series B Financing June 18th, 2015

Pixelligent Closes $3.4 Million in Funding: Capital Will Be Used to Support Partner & Customer Product Introductions and Increase Manufacturing Capacity June 16th, 2015

Announcements

BASF and Fraunhofer IPMS-CNT jointly develop electronic materials June 30th, 2015

Graphene flexes its electronic muscles: Rice-led researchers calculate electrical properties of carbon cones, other shapes June 30th, 2015

Researchers from the UCA, key players in a pioneering study that may explain the origin of several digestive diseases June 30th, 2015

Oxford Instruments’ TritonXL Cryofree dilution refrigerator selected for the Oxford NQIT Quantum Technology Hub project June 30th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project